# Import the tidied data.
library(DT)
data <- read.csv(file = "/Users/far/Desktop/Felicia Far/JHU/Spring 2024/Sustainable Finance/Final Project/Clean Data.csv", header = TRUE, sep = ",", quote = "\"",
dec = ".", fill = TRUE, comment.char = "")
datatable(data, options = list(pageLength = 5))Final Project: Rough Draft Due
Introduction and Rationale
In the ever-evolving landscape of the biotechnology industry, the correlation between sustainability efforts and financial performance has sparked considerable interest among investors, policymakers, and industry stakeholders. As environmental, social, and governance (ESG) criteria continue to influence the investment strategies and corporate actions, it becomes imperative to scrutinize the specific impact of these initiatives on the stock prices of biotech companies.
This analysis aims to dissect the nuanced relationship between sustainability practices and market performance within the biotech sector, leveraging insights from previous studies and financial data sources such as Yahoo Finance. We will explore the direct effects of sustainability on stock prices, delve into the mechanisms driving these effects, and consider the potential for industry-specific patterns. Our findings are intended to offer valuable perspectives to a diverse audience comprising biotech investment entities, consulting agents, and ESG auditing firms that together form the analytical backbone of the biotech industry’s approach to sustainable development.
Audience inlcudes companies targeting biotech investments, biotech companies and their consulting agents that target a growth in stock price (or financial performance), and those ESG auditing companies creating frameworks and measurement for biotech industry.
Methodology
Current two variables are stock price and ESG rating: Stock price from May 2018 to Apr 2024 will be recorded from Yahoo Finance on a monthly basis, which is the stock close price on the first day of each month. ESG rating will adopt MSCI ESG rating from 2019 to 2023. Assume each rating accurately captures the company’s ESG level of compliance until the next rating is published. The rating is given on a scale of AAA, AA, A, BBB, BB, B, CCC; For the ease of further analysis, the elements are each assigned a number, with AAA labeled 7 and CCC labeled 1.
Ten mega healthcare industry companies are chosen, with majority included in S&P 500. The criteria of screening is not only the business size, but more importantly that their MSCI ESG rating is available for MSCI only rated a limited number of mega companies.
The Tidied data is saved as a new csv file that can be directly imported for later analysis.
Analysis & Insights
Visualization 1
library(ggplot2)
library(dplyr)
Attaching package: 'dplyr'The following objects are masked from 'package:stats':
filter, lagThe following objects are masked from 'package:base':
intersect, setdiff, setequal, unionlibrary(lubridate)
Attaching package: 'lubridate'The following objects are masked from 'package:base':
date, intersect, setdiff, unionlibrary(scales)
data$Date <- as.Date(data$Date, format="%Y-%m-%d")
data_summary <- data %>%
group_by(Month = floor_date(Date, "month")) %>%
summarise(AverageStockPrice = mean(Stock.Price, na.rm = TRUE),
AverageESGRating = mean(ESG.Rating, na.rm = TRUE))
p <- ggplot(data_summary, aes(x = Month)) +
geom_line(aes(y = AverageStockPrice, group = 1), color = "blue") +
geom_line(aes(y = AverageESGRating*100, group = 1), color = "red") +
scale_y_continuous(name = "Average Stock Price", sec.axis = sec_axis(~./100, name = "Average ESG Rating (Scaled)")) +
labs(title = "Trend of Average Stock Price and ESG Rating Over Time", x = "Date") +
theme_minimal()
print(p)Warning: Removed 13 rows containing missing values (`geom_line()`).
A combined visualization of average stock prices and ESG ratings offers a snapshot of how sustainability measures might influence investor behavior and corporate valuation in the biotech sector. It allows for a direct, visual correlation between a company’s ESG commitment and its market performance over time. If both metrics show a positive trend, it could indicate that investors reward higher ESG scores with higher stock valuations, suggesting a financial incentive for biotech firms to adopt sustainable practices. Conversely, if higher ESG ratings do not correlate with stock performance, it may prompt a reevaluation of how sustainability efforts are communicated or executed. For stakeholders, this graph acts as a barometer for measuring the tangible benefits of sustainability in the marketplace, potentially guiding investment strategies and corporate governance. In an industry that is inherently future-focused, this visualization encapsulates the financial viability and ethical considerations of integrating ESG into business models.
Visualization 2
data$ESGCategory <- ifelse(data$ESG.Rating > median(data$ESG.Rating, na.rm = TRUE), "High", "Low")
data %>%
filter(!is.na(ESG.Rating)) %>%
group_by(Year = year(Date), ESGCategory) %>%
summarise(AverageStockPrice = mean(Stock.Price, na.rm = TRUE)) %>%
ggplot(aes(x = Year, y = AverageStockPrice, color = ESGCategory)) +
geom_line() +
labs(title = "Stock Price Trends by ESG Rating Category", x = "Year", y = "Average Stock Price")`summarise()` has grouped output by 'Year'. You can override using the
`.groups` argument.
The graph delineates the trajectory of average stock prices for biotech companies over a span of five years, bifurcated by their ESG (Environmental, Social, and Governance) ratings into high and low categories. Starting in 2019, the stock prices of both categories appear closely aligned. However, as time progresses, a discernible divergence emerges. Companies classified with high ESG ratings exhibit a consistent and marked ascension in stock value, notably experiencing a steep increase post-2023. In contrast, firms with lower ESG ratings display a more modest upward trend, marred by a temporary decline around 2022, after which the prices recover and continue to climb, albeit at a less pronounced rate than their high-ESG counterparts. By 2024, there is a substantial disparity in the average stock prices between the two groups, indicating that the market potentially favors companies with robust sustainability practices. This observation suggests that higher ESG ratings may correlate with superior stock market performance, possibly reflecting investor preference for sustainable and ethically operated companies. However, it is imperative to consider this analysis within the broader context of the biotech sector’s dynamics and individual company performance to fully understand the factors influencing these trends.
Visualization 3
ggplot(data, aes(x = ESG.Rating, y = Stock.Price)) +
geom_point() +
geom_smooth(method = lm) +
labs(title = "Correlation Between Stock Prices and ESG Ratings", x = "ESG Rating", y = "Stock Price")`geom_smooth()` using formula = 'y ~ x'Warning: Removed 181 rows containing non-finite values (`stat_smooth()`).Warning: Removed 181 rows containing missing values (`geom_point()`).
The faceted line chart creates distinct visual segments for biotech companies categorized by high and low ESG ratings, offering a clear comparative analysis of stock price trends within these segments. This visualization is significant for discerning whether sustainable practices, as reflected by ESG ratings, have a differentiated impact on financial performance. It facilitates a side-by-side assessment that can highlight whether companies with higher sustainability standards perform better, worse, or similarly in the stock market compared to their lower-rated peers. By isolating each category, the chart eliminates the noise that could be present in a combined plot and allows for a focused analysis on the nuanced financial trajectory of each ESG tier. This targeted view can inform investors and stakeholders about the potential return on investment in sustainability and drive strategic decision-making within the biotech industry, centered on the integration of ESG considerations.
Visualization 4
data %>%
group_by(Year = year(Date), ESGCategory) %>%
summarise(AverageStockPrice = mean(Stock.Price, na.rm = TRUE)) %>%
mutate(YearlyChange = AverageStockPrice - lag(AverageStockPrice)) %>%
ggplot(aes(x = Year, y = YearlyChange, fill = ESGCategory)) +
geom_bar(stat = "identity", position = "dodge") +
labs(title = "Yearly Average Stock Price Change by ESG Rating Category", x = "Year", y = "Yearly Change in Average Stock Price")`summarise()` has grouped output by 'Year'. You can override using the
`.groups` argument.Warning: Removed 7 rows containing missing values (`geom_bar()`).
By categorizing companies based on their ESG performance, it offers insights into how sustainability efforts influence stock price dynamics over time. A consistent pattern of positive stock price changes among companies with higher ESG ratings suggests that investors reward sustainability initiatives, signaling a market preference for socially responsible investments. Conversely, if stock price changes show little correlation with ESG ratings, it prompts a reevaluation of the effectiveness of current sustainability strategies and their perceived value in the market. This visualization informs investment decisions, corporate sustainability initiatives, and strategic planning, highlighting the evolving relationship between sustainability practices and financial performance in the biotech industry.
Conclusion
The comprehensive analysis of the biotechnology sector in relation to Environmental, Social, and Governance (ESG) criteria demonstrates a positive correlation between ESG ratings and stock price performance over the period from 2019 to 2024. This trend underscores the growing importance of sustainability practices in the valuation of biotech companies by the market. As investors and stakeholders increasingly prioritize ESG metrics, companies exhibiting higher ESG scores have been rewarded with enhanced stock valuations, suggesting a shift in investor preferences towards ethically and sustainably operated entities.
The divergence in stock price trajectories based on ESG ratings highlights a clear market distinction, with companies that prioritize and effectively communicate their sustainability efforts experiencing more robust financial performance. This not only reflects the integration of ESG considerations into strategic planning but also indicates that sustainable practices are becoming critical components of corporate value creation.
However, the data also suggests that the impact of ESG ratings on stock prices is not uniform across the biotech industry. There are instances where stock price changes show little to no correlation with ESG ratings, prompting further investigation into the effectiveness of these initiatives and their communication to the market. It may indicate that certain sectors within the biotech industry still need to establish stronger links between sustainability actions and financial performance.
In conclusion, this analysis illuminates the evolving landscape of the biotech industry, where sustainability is progressively being integrated into the core business model, influencing not only corporate governance but also financial outcomes. As the industry continues to develop, biotech companies may need to adopt more transparent and effective ESG practices to meet the expectations of an increasingly discerning investor base. This trend towards sustainability is not a transient market anomaly but appears to be a fundamental shift in how biotech companies are evaluated and how they operate within the global marketplace. The findings of this study serve as a strategic indicator for companies that effective implementation and reporting of ESG practices can lead to enhanced market performance and competitive advantage.
References
Cho J, Singh M, Lo AW. How does news affect biopharma stock prices?: An event study. PLoS One. 2024;19(1):e0296927. Published 2024 Jan 26. doi:10.1371/journal.pone.0296927
Juan Piñeiro-Chousa, M. Ángeles López-Cabarcos, Lara Quiñoá-Piñeiro, Ada M. Pérez-Pico, US biopharmaceutical companies’ stock market reaction to the COVID-19 pandemic. Understanding the concept of the ‘paradoxical spiral’ from a sustainability perspective, Technological Forecasting and Social Change, Volume 175, 2022, 121365, ISSN 0040-1625, https://doi.org/10.1016/j.techfore.2021.121365
La Torre M, Mango F, Cafaro A, Leo S. Does the ESG Index Affect Stock Return? Evidence from the Eurostoxx50. Sustainability. 2020; 12(16):6387. https://doi.org/10.3390/su12166387
Simin Chen, Yu Song, Peng Gao, Environmental, social, and governance (ESG) performance and financial outcomes: Analyzing the impact of ESG on financial performance, Journal of Environmental Management, Volume 345, 2023, 118829, ISSN 0301-4797, https://doi.org/10.1016/j.jenvman.2023.118829